Press Releases
<< Back
Horizon Technology Finance Provides Second Quarter 2019 Portfolio Update
"We had another active and successful quarter at Horizon, driven by the ongoing strength and demand for our venture debt loans and the overall venture debt loan market," said
Originations
Horizon funded eight loans during the second quarter of 2019 totaling
$15.0 million to a new portfolio company,Encore Dermatology, Inc. , a fully integrated specialty dermatology company committed to delivering innovative prescription therapies and medical devices to dermatologists while focusing on customer service and improving the quality of life of patients.$12.5 million to an existing portfolio company,Bridge2 Solutions, LLC , a SaaS platform technology company providing innovative solutions to drive engagement and loyalty between brands and their consumers.$8.0 million to a new portfolio company,OutboundEngine, Inc. , a leading provider of B2B marketing automation software that empowers small business owners with actionable marketing campaigns.$6.0 million to an existing portfolio company,CSA Medical, Inc. , a developer of novel, patent-protected cryotherapy medical devices.$5.0 million to an existing portfolio company,Catasys, Inc. , a leading AI and technology-enabled healthcare company.$5.0 million to a new portfolio company, a SaaS marketing data and CRM platform specialized for the hospitality industry.$3.0 million to a new portfolio company,Meditrina, Inc. , anFDA cleared medical device company focused on developing fully disposable endoscopes and an office-based platform that can address multiple procedures for gynecologists.$0.6 million to an existing portfolio company,Audacy Corporation , a space communications service provider focused on delivering continuous connectivity and space data in real time.
Liquidity Events
Horizon experienced liquidity events from eight portfolio companies in the second quarter of 2019, which encompassed outstanding principal prepayments of
- In April,
Powerhouse Dynamics, Inc. ("Powerhouse") prepaid its outstanding principal balance of$0.4 million on its venture loan, plus interest, end-of-term payment and prepayment fee. Powerhouse also completed a sale transaction from which Horizon received proceeds of approximately$0.1 million in connection with the termination of Horizon's warrants in Powerhouse. - In May,
Aerin Medical, Inc. ("Aerin") prepaid its outstanding principal balance of$10.0 million on its venture loan, plus interest, end-of-term payment and prepayment fee. Horizon continues to hold warrants in Aerin. - In May, with the proceeds of a new loan from Horizon,
Bridge2 Solutions, LLC ("Bridge2") prepaid its previously outstanding principal balance of$10.0 million on its venture loan, plus interest and end-of-term payment. Horizon continues to hold warrants in Bridge2. - In May,
Zinio Holdings, LLC ("Zinio") prepaid its outstanding principal balance of$2.4 million on its venture loan, plus interest, end-of-term payment and prepayment fee. Horizon also received a$0.2 million success fee from Zinio. - In June,
Education Elements, Inc. ("Education Elements") prepaid its outstanding principal balance of$0.2 million on its venture loan, plus interest, end-of-term payment and prepayment fee. Horizon continues to hold warrants in Education Elements. - In June,
Jump Ramp Games, Inc. prepaid its outstanding principal balance of$4.0 million on its venture loan, plus interest and end-of-term payment. - In June,
Kixeye, Inc. ("Kixeye") prepaid its outstanding principal balance of$4.5 million on its venture loan, plus interest, end-of-term payment and prepayment fee. In connection with the prepayment of the venture loan, Horizon received a warrant inGlobal Worldwide LLC , a successor to Kixeye. - In June,
TruSignal, Inc. ("TruSignal") closed a sale transaction from which Horizon received proceeds of approximately$0.1 million in connection with the sale of Horizon's equity investment in TruSignal.
Subsequent Event
Subsequent to the second quarter, Horizon funded a
Joint Venture Activity
During the second quarter of 2019, Horizon transferred portions of two of its portfolio investments, totaling
$5.0 million of venture loans toMustang Bio, Inc. , a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.$5.0 million of venture loans toEncore Dermatology, Inc. , a fully integrated specialty dermatology company committed to delivering innovative prescription therapies and medical devices to dermatologists while focusing on customer service and improving the quality of life of patients.
Principal Payments Received
During the second quarter of 2019, Horizon received regularly scheduled principal payments on investments totaling
Commitments
During the second quarter ended
Pipeline
As of
Capital Markets Activity, Warrant and Equity Portfolio
As of
About
Forward-Looking Statements
Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon's filings with the
Contacts:
Investor Relations:
ICR
ir@horizontechfinance.com
(860) 284-6450
Media Relations:
ICR
brian.ruby@icrinc.com
(203) 682-8268
View original content:http://www.prnewswire.com/news-releases/horizon-technology-finance-provides-second-quarter-2019-portfolio-update-300882775.html
SOURCE